Physician profile
Simon N Allo
NPI 1841375177
$621.71
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2021: $43.20 · 2022: $42.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $130.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $110.23 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $92.43 | 2019 | |
| Amgen INC. | $83.87 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $51.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.10 | 2019-2021 | |
| Pfizer INC. | $32.75 | 2019 | |
| Braemar Manufacturing, LLC | $20.53 | 2019 | |
| Abbott Laboratories | $20.00 | 2021 | |
| Amarin Pharma, INC. | $18.00 | 2019 | |
| Teleflex LLC | $16.57 | 2022 | |
| Medtronic, INC. | $11.91 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Allo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.